Abstract:Abstract Background and Aims Serum creatinine has been widely utilized to estimate glomerular filtration rate (eGFR), although various biomarkers have been developed to address its limitations. Among these biomarkers, the clinical use of Cystatin C is increasingly gaining recognition. However, there is a lack of evaluation regarding the utility of cystatin C in predicting the risk of postoperative acute kidney injury (PO-AKI) in non-cardiac surgeries. Method A retrospective cohort study was conducted on patients who underwent non-cardiac surgeries more than 1 hour from five departments (general surgery, neurosurgery, obstetrics and gynecology [OBGY], orthopedics, and urosurgery) at Chung-Ang University Hospital between 2018 and 2020. Patients with missing baseline information, including creatinine and cystatin C, and those without follow-up serum creatinine levels were excluded. PO-AKI was defined as KDIGO-AKI criteria occurring within 7 days after surgery. The estimated glomerular filtration rate (eGFR) was calculated from 2012 and 2021 chronic kidney disease-epidemiology collaboration (CKD-EPI) equations. Logistic regression was used to develop a prediction model, and C-statistics and the Delong test were used to compare the performance. Baseline comorbidities (diabetes mellitus [DM] and hypertension), laboratory findings (hypoalbuminemia [serum albumin <3.5 g/dL], anemia [hemoglobin <12 g/dL for female or <13 g/dL for male], and hyponatremia [sodium <135 mEq/L]), medication usage within 90 days of surgery (nonsteroidal anti-inflammatory drug and renin-angiotensin-system [RAS] blocker), and operation information (Anesthesia type, emergency operation, and operation duration) were adjusted. Results Overall, 339 patients were enrolled, with 49 patients (14.5%) developed PO-AKI. The median age was 73.0 [64.0; 80.0]; eGFR-Cr 86.4 [65.5; 99.1] mL/min/1.73 m2, eGFR-Cystatin C 70.0 [45.2; 92.7] mL/min/1.73 m2; eGFR-Cr/Cystatin C 77.2 [54.5; 100.5] mL/min/1.73 m2. Patients who developed AKI had a higher prevalence of diabetes (AKI 49.0%, no AKI 28.3%; p-value 0.006) and prescription of RAS blockers (AKI 63.3%, no AKI 34.5%; p-value <0.001), longer operation duration (AKI 63.3%, no AKI 34.5%; p-value <0.001), and lower eGFR of all types (AKI: eGFR-Cr 69.8, eGFR-Cystatin C 48.0, eGFR-Cr/Cystatin C 57.2; no-AKI: eGFR-Cr 88.0, eGFR-Cystatin C 74.0, eGFR-Cr/Cystatin C 80.5 mL/min/1.73 m2; p-values <0.001). No statistical differences were observed in other laboratory findings between the two groups (Table 1). The model with eGFR-Cystatin C demonstrated the highest area under the curve (AUC) among the three models (eGFR-Cr: AUC 0.78, 95% confidential interval [CI] 0.702‒0.857; eGFR-Cystatin C: AUC 0.81, 95% CI 0.735‒0.877; eGFR-Cr/Cystatin C: AUC 0.80, 95% CI 0.724‒0.871). Only the eGFR-Cystatin C-based model showed significant improvement in prediction compared to the eGFR-Cr-based model in the Delong test (eGFR-Cystatin C vs eGFR-Cr: p-value 0.033; eGFR-Cr/Cystatin C vs eGFR-Cr: p-value 0.055, Fig. 1). Conclusion Our findings suggest the potential usefulness of cystatin C in predicting the risk of PO-AKI non-cardiac surgery in addition to conventional PO-AKI risk factors. Further studies including larger and external cohorts, are needed for validation.

Elevated serum cystatin C at continuous renal replacement therapy initiation predicts lack of renal recovery.

Elevated Serum Cystatin C at Continuous Renal Replacement Therapy Initiation Predicts Lack of Renal Recovery

Serum Cystatin C is Associated with Renal Function Recovery in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy

Serum Cys C Predicts Acute Kidney Injury in Patients with Acute Pancreatitis: A Retrospective Study.

Cystatin C in Prediction of Acute Kidney Injury: A Systemic Review and Meta-analysis

The Impact of Serum Cystatin C on Short Term Prognosis in Petients With Ischemic Heart Failure

Cystatin C and Kidney Function Recovery in Patients Requiring Continuous Kidney Replacement Therapy for Acute Kidney Injury

In Reply to 'serum Cystatin C May Diagnose Rather Than Predict Acute Kidney Injury'

Long-term Renal and Overall Survival of Critically Ill Patients with Acute Renal Injury Who Received Continuous Renal Replacement Therapy.

Clinical analysis of continuous renal replacement therapy in patients with acute kidney injury in ICU

Predictive value of serum creatinine/cystatin C in neurocritically ill patients

Diagnostic Accuracy of Plasma Cystatin C and Renal Resistive Index for Acute Kidney Injury in Critically Ill Patients: A Prospective Observational Study

#767 Utility of cystatin C as a predictor for postoperative acute kidney injury in non-cardiac surgeries [S1]

Effect of early increase of serum cystatin C on prognosis of patients after resuscitation

Assessment of Cystain C and albumin/creatinine ratio in critical patients with acute kidney injury

The clinical outcomes of acute kidney injury substages based on serum cystatin C in pediatric patients undergoing cardiac surgery

Predictors of Augmented Renal Clearance in a Heterogeneous ICU Population as Defined by Creatinine and Cystatin C

Serum cystatin C as a predictor for cardiovascular events in end-stage renal disease patients at the initiation of dialysis

Baseline serum cystatin C as a marker of acute kidney injury in patients with acute-on-chronic liver failure

Serum Cystatin C as a Marker of Renal Function in Critically Ill Patients With Normal Serum Creatinine

Using Serum Cystatin C to Predict Acute Kidney Injury Following Infant Cardiac Surgery